Browse > Article
http://dx.doi.org/10.4333/KPS.2011.41.5.309

Bioequivalence Assessment of Acephyll® Capsule to Surfolase® Capsule (Acebrophylline HCl 100 mg) by Liquid Chromatography Tandem Mass Spectrometry  

Nam, Kyung-Don (College of Pharmacy, Kyung Hee University)
Seo, Ji-Hyung (College of Pharmacy, Kyung Hee University)
Yim, Sung-Vin (College of Medicine, Kyung Hee University)
Lee, Kyung-Tae (College of Pharmacy, Kyung Hee University)
Publication Information
Journal of Pharmaceutical Investigation / v.41, no.5, 2011 , pp. 309-315 More about this Journal
Abstract
A sensitive and specific liquid chromatographic method coupled with tandem mass spectrometry (LC-MS/MS) was developed for the analysis of ambroxol (active moiety of acebrophylline). After acetonitrile precipitation of proteins from plasma samples, ambroxol and the domperidone (internal standard, IS) were eluted on a C18 column. The isocratic mobile phase was consisted of 10 mM ammonium acetate and methanol (10 : 90, v/v), with flow rate at 0.2 mL/min. A tandem mass spectrometer, as detector, was used for quantitative analysis in positive mode by a multiple reaction monitoring mode to monitor the m/z 379.2${\rightarrow}$264.0 and the m/z 426.2${\rightarrow}$175.1 transitions for ambroxol and the IS, respectively. Twenty four healthy Korean male subjects received two capsules (100 mg ${\times}$ 2) of either the test or the reference formulation of acebrophylline HCl in a 2 ${\times}$ 2 crossover study, this was followed by a 1week washout period between either formulation. $AUC_{0-t}$ (the area under the plasma concentration-time curve) was calculated by the linear trapezoidal rule. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. The 90% confidence intervals for the log transformed data were acceptable range of log 0.8 to log 1.25 (e.g., log 0.8964 - log 0.9910 for $AUC_{0-t}$ log 0.8690 - log 1.0750 for $C_{max}$). The major parameters, $AUC_{0-t}$ and $C_{max}$ met the criteria of Korea Food and Drug Administration for bioequivalence indicating that Acephyll$^{(R)}$ capsule (test) is bioequivalent to Surfolase$^{(R)}$ capsule (reference).
Keywords
Liquid chromatography/tandem mass spectrometry; Ambroxol; Bioequivalence; Acephyll$^{(R)}$ capsule; Surfolase$^{(R)}$ capsule;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Lee, Y.J., Choi, J.H., Song, S.H., Seo, C.H., Kim, D.S., Park, I.S., Choi, K.H., Na, H.K., Chung, S.J, Lee, M.H. and Shim, C.K., 1998. Development of K-BEtest, a computer program for the analysis of bioequivalence J. Kor. Pharm. Sci. 28, 223-229.   과학기술학회마을
2 Lee, Y.J. Kim, Y.G., Lee, M.G., Chung, S.J., Lee, M.H., Shim, C.K., 2000. Analysis of bioequivalence study using log-transformed model Yakhakhoeji. 44, 308-314
3 Pozzi, E., 2007. Acebrophylline: an airway mucoregulator and anti-infalmmatory agent, Monaldi. Arch. Chest. Dis., 67(2), 106-15.
4 Yoo, J.Y., Joung, S.K., Choe, M.H., Han, S.B., Lee, K.R., Lee, H.J., 2003. Bioequivalence of $ambrect^{TM}$ Tablet J. Kor. Pharm. Sci., 35(3), 215-221.   과학기술학회마을   DOI
5 Angelo, L.D., 1992. Plasma levels and pharmacokinetic parameters of ambroxol and theophylline-7-acetic acid in adults after single and repeated acebrophylline doses, Italian J. chest Diseases, 85-89.
6 Cho, H.Y., Park, E.J., Kang, H.H., Kim, S.M., Park, C.H., Oh, I.J., Lim, D.K., Lee M.H., Lee, Y.B., 2005. Bioequivalence of Burophil Capsule to Surfolase Capsule, J. Kor. Pharm. Sci., 35(3), 179-185.   과학기술학회마을   DOI
7 Hang, T.J. et al., 2007. simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS, Clinical Chimica Acta. 382, 20-24.   DOI   ScienceOn
8 Hyundai Pharm, Co., Ltd., 1998. $Sulfolase^{\circledR}$capsule Drug Information, 7-8.
9 Korea FDA, 2003 Guideline for the Validation of Bioanalytical Method 2003. 05.
10 Korea FDA, 2005 Guideline for Bioequivalence Test 2005-31.
11 Korea FDA, 2007 Guideline for Korean Good Clinical Practice 2007-34.